Technology evaluation: IMC-1C11, ImClone Systems.
ImClone is developing IMC-IC11, an anti-angiogenesis chimeric monoclonal antibody specific vascular endothelial growth factor receptor 2 (VEGFR-2, also known Flk-1 in mice), for the potential treatment of cancer [156625]; it in phase I trials for the treatment of colorectal carcinoma [379143]. The related antibody DC-101 provided proof-of-principle that an anti-VEGF receptor antibody could strongly inhibit tumor growth and even cause tumor regression with the glioblastoma tumor cell line, GBM18 [388236]. In May 1998, the company was granted US-05747651 by the USPTO, covering antibodies against the extracellular portion of the FLK-1/KDR receptor [284054].
Hunt
S
S
dshunt@easynet.co.uk
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000628:therapy*; D006801:Humans; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D017978:Receptors, Growth Factor; D011993:Recombinant Fusion Proteins; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor